ArticleJournal of drug delivery science and technology2021
Graphene quantum dots decorated with imatinib for leukemia treatment.
Article in Journal of drug delivery science and technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Melt-Extruded Microparticles Based On Chitosan-pectin Complex for Delayed Dissolution of Benznidazole.AAPS PharmSciTech · 2025Article
- Strategies to Overcome Challenges in Formulating Tablets from Dried Plant Extracts: a Comprehensive Review.AAPS PharmSciTech · 2025Review
- Bioinspired quantum dots: advancing diagnostic and therapeutic strategies in breast cancer.RSC advances · 2025Review
- Review
- Insight into the Recent Developments of Nanoparticles in Treatment of Cancer and Neuro-Degenerative Disease: A Review.Current topics in medicinal chemistry · 2025Review
- Recent Biomedical Applications of Carbon Quantum Dots in Cancer Treatment.The journal of physical chemistry. C, Nanomaterials and interfaces · 2024Article
- Surface Modification of Mesoporous Silica Nanoparticles for Application in Targeted Delivery Systems of Antitumour Drugs.Polymers · 2024Review
- Molecular Imaging for Lung Cancer: Exploring Small Molecules, Peptides, and Beyond in Radiolabeled Diagnostics.Pharmaceutics · 2024Review
- Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials.European journal of medical research · 2023Review
- Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems.Pharmaceutics · 2023Review
- Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology.EJNMMI radiopharmacy and chemistry · 2022Review
- The Promise of Nanotechnology in Personalized Medicine.Journal of personalized medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 3 countries.
Funding
Abstract
The use of graphene quantum dots as biomedical device and drug delivery system has been increasing. This nanoplatform of pure carbon has showed unique properties and showed to be safe for human use. The imatinib is a molecule designed to specifically inhibit the tyrosine kinase, used for leukemia treatment. In this study, we successfully decorated the graphene quantum dots (GQDs@imatinb) by a carbodiimide crosslinking reaction. The GQDs@imatinb were characterized by FTIR and AFM. The nanoparticles' in vitro behaviors were evaluated by cellular trafficking (internalization) assay and cell viability and apoptosis assays in various cancer cell lines, including suspension (leukemia) cells and adherent cancer cells. The results showed that the incorporation of the imatinib on the surface of the graphene quantum dots did not change the nanoparticles' morphology and properties. The GQDs@imatinb could be efficiently internalized and kill cancer cells via the induction of apoptosis. The data indicated that the prepared GQDs@imatinb might be a great drug nano-platform for cancer, particularly leukemia treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.